iSpecimen Inc
NASDAQ:ISPC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
E-House (China) Enterprise Holdings Ltd
HKEX:2048
|
CN |
iSpecimen Inc
Total Current Assets
iSpecimen Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
iSpecimen Inc
NASDAQ:ISPC
|
Total Current Assets
$3.6m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Total Current Assets
$8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
28%
|
CAGR 10-Years
32%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Total Current Assets
$583.7m
|
CAGR 3-Years
3%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Total Current Assets
$1.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Total Current Assets
$680.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
10%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Total Current Assets
$308.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
iSpecimen Inc
Glance View
iSpecimen, Inc. operates as healthcare organization that engages in procurement of human biospecimens. The company is headquartered in Lexington, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2021-06-17. The firm designed iSpecimen Marketplace platform to transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. The Company’s marketplace platform ingests de-identified healthcare data provided by healthcare supply partners. The iSpecimen Marketplace supports the supply chain management and bioprocurement process for specimens and associated data. The Company’s platform helps with administrating and reporting function for researchers, suppliers, and internal personnel, including user and compliance management. The firm serves to biopharmaceutical companies, in vitro diagnostic (IVD) companies, and government/academic institutions.
See Also
What is iSpecimen Inc's Total Current Assets?
Total Current Assets
3.6m
USD
Based on the financial report for Dec 31, 2024, iSpecimen Inc's Total Current Assets amounts to 3.6m USD.
What is iSpecimen Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
18%
Over the last year, the Total Current Assets growth was -56%. The average annual Total Current Assets growth rates for iSpecimen Inc have been -52% over the past three years , 18% over the past five years .
